Drug Interaction Study Between Dorzagliatin and Empagliflozin
Status:
Completed
Trial end date:
2020-03-15
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of
glucokinase activator dorzagliatin and empagliflozin in subjects with T2DM. Pharmacokinetics
and pharmacodynamics when dorzagliatin and empagliflozin given alone and in combination will
be studied.